Supplements reduce risk among children with low serum 25(OH)D and have beneficial effects in children with atopic dermatitis, allergic rhinitis<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, Nov. 21, 2022 (HealthDay News) — Vitamin D supplementation does not reduce the risk for asthma exacerbation in children overall, but does reduce the risk in those with low serum 25-hydroxyvitamin D (25[OH]D) concentrations, according to a review recently published in Nutrients<\/em>.<\/p>\n Qinyuan Li, M.D., from the Chongqing Key Laboratory of Pediatrics in China, and colleagues conducted a systematic review and meta-analysis to examine the effects of vitamin D supplementation in children with allergic diseases. Data were included from 32 randomized controlled trials (RCTs) comparing vitamin D supplementation with placebo among 2,347 children.<\/p>\n The researchers found that compared with placebo, vitamin D supplementation did not reduce the risk for asthma exacerbations overall (risk ratio, 0.84; 95 percent confidence interval, 0.65 to 1.08; P = 0.18), but there was a reduction observed in the risk for asthma exacerbation for children with baseline serum 25(OH)D <10 ng\/mL (risk ratio, 0.48; 95 percent confidence interval, 0.28 to 0.83; P = 0.009). A significant reduction was seen in the Scoring Atopic Dermatitis or the Eczema Area and Severity Index scores in children with atopic dermatitis with vitamin D versus placebo (standardized mean difference, \u00e2\u0088\u00920.5; 95 percent confidence interval, \u00e2\u0088\u00920.87 to \u00e2\u0088\u00920.12; P = 0.009). For children with allergic rhinitis, vitamin D supplementation reduced the symptom-medication score compared with placebo (mean, 43.7 versus 57.8).<\/p>\n “Large-scale and well-designed RCTs are needed to confirm these conclusions and investigate the optimum regimen of vitamin D and the patients who would benefit most from vitamin D supplementation,” the authors write.<\/p>\n